UCB
ISIN: BE0003739530 | Ticker: UCB | LEI: 2138008J191VLSGY5A09
Country: Belgium
A global biopharma company, inspired by the needs of people living with severe diseases.
At UCB, we are consistently delivering on our commitment to improve the lives of people living with severe neurological and immunological conditions. And thanks to our focused, innovative and trusted solutions, our business is strong.
Our people have lived our purpose each day since 1928, making critical investments in biopharmaceutical research and leading innovations that strive to achieve a meaningful impact on the lives of those we serve.
UCB’s ambition is to transform the lives of people living with severe diseases, allowing them to live the best life that they can – as free as possible from the challenges and uncertainty of disease. That commitment comes to life in our research and development activities across neurology, immunology and other areas where our expertise, innovation and ambition align with unmet needs.
1928
Served areaWorldwide
Headcount8,600
HeadquartersAllée de la Recherche 60, 1070 Bruxelles, Bruxelles-Capitale – Belgium
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 |
|---|---|---|---|
| Assets | N/A | 13,319,000,000.00 | 14,210,000,000.00 |
| Noncurrent Assets | N/A | 9,737,000,000.00 | 10,500,000,000.00 |
| Property Plant And Equipment | N/A | 1,035,000,000.00 | 1,275,000,000.00 |
| Goodwill | N/A | 4,964,000,000.00 | 5,173,000,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 2,973,000,000.00 | 3,159,000,000.00 |
| Deferred Tax Assets | N/A | 605,000,000.00 | 692,000,000.00 |
| Current Assets | N/A | 3,582,000,000.00 | 3,710,000,000.00 |
| Inventories | N/A | 854,000,000.00 | 878,000,000.00 |
| Trade And Other Current Receivables | N/A | 1,031,000,000.00 | 1,239,000,000.00 |
| Current Tax Assets Current | N/A | 48,000,000.00 | 51,000,000.00 |
| Cash and cash equivalents | N/A | 1,336,000,000.00 | 1,263,000,000.00 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | N/A | 3,000,000.00 | 6,000,000.00 |
| Equity And Liabilities | N/A | 13,319,000,000.00 | 14,210,000,000.00 |
| Equity | 7,009,000,000.00 | 7,272,000,000.00 | 8,386,000,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 7,271,000,000.00 | 8,386,000,000.00 |
| Noncontrolling Interests | N/A | 1,000,000.00 | 0.00 |
| Liabilities | N/A | 6,047,000,000.00 | 5,824,000,000.00 |
| Noncurrent Liabilities | N/A | 3,233,000,000.00 | 3,000,000,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 402,000,000.00 | 315,000,000.00 |
| Other Longterm Provisions | N/A | 165,000,000.00 | 188,000,000.00 |
| Noncurrent Payables | N/A | 91,000,000.00 | 86,000,000.00 |
| Deferred Tax Liabilities | N/A | 168,000,000.00 | 191,000,000.00 |
| Current Tax Liabilities Noncurrent | N/A | 88,000,000.00 | 139,000,000.00 |
| Other Noncurrent Financial Liabilities | N/A | 3,000,000.00 | 13,000,000.00 |
| Longterm Borrowings | N/A | 1,629,000,000.00 | 1,252,000,000.00 |
| Noncurrent Portion Of Noncurrent Bonds Issued | N/A | 687,000,000.00 | 816,000,000.00 |
| Current Liabilities | N/A | 2,814,000,000.00 | 2,824,000,000.00 |
| Other Shortterm Provisions | N/A | 80,000,000.00 | 83,000,000.00 |
| Trade And Other Current Payables | N/A | 2,138,000,000.00 | 2,555,000,000.00 |
| Current Tax Liabilities Current | N/A | 79,000,000.00 | 31,000,000.00 |
| Other Current Financial Liabilities | N/A | 86,000,000.00 | 100,000,000.00 |
| Liabilities Included In Disposal Groups Classified As Held For Sale | N/A | 0.00 | 0.00 |
| Current Borrowings And Current Portion Of Noncurrent Borrowings | N/A | 81,000,000.00 | 55,000,000.00 |
| Current Bonds Issued And Current Portion Of Noncurrent Bonds Issued | N/A | 350,000,000.00 | 0.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
|---|---|---|
| Revenue | 5,347,000,000.00 | 5,777,000,000.00 |
| Revenue From Sale Of Goods | 5,052,000,000.00 | 5,471,000,000.00 |
| Revenue From Royalties | 96,000,000.00 | 79,000,000.00 |
| Other Revenue | 199,000,000.00 | 227,000,000.00 |
| Other Gains Losses | -102,000,000.00 | -7,000,000.00 |
| Profit Loss From Operating Activities | 971,000,000.00 | 1,284,000,000.00 |
| Finance Income | 14,000,000.00 | 80,000,000.00 |
| Finance Costs | 107,000,000.00 | 138,000,000.00 |
| Profit Loss Before Tax | 880,000,000.00 | 1,226,000,000.00 |
| Income Tax Expense Continuing Operations | 119,000,000.00 | 170,000,000.00 |
| Profit Loss From Continuing Operations | 761,000,000.00 | 1,056,000,000.00 |
| Profit Loss From Discontinued Operations | 0.00 | 3,000,000.00 |
| Profit (loss) | 761,000,000.00 | 1,058,000,000.00 |
| Profit Loss Attributable To Owners Of Parent | 732,000,000.00 | 1,058,000,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 29,000,000.00 | 0.00 |
| Line item in (eur) | 01.01.2021 | 01.01.2022 |
|---|---|---|
| Profit (loss) | 761,000,000.00 | 1,058,000,000.00 |
| Adjustments For Undistributed Profits Of Associates | 2,000,000.00 | 0.00 |
| Other Adjustments For Noncash Items | 297,000,000.00 | 239,000,000.00 |
| Other Adjustments For Which Cash Effects Are Investing Or Financing Cash Flow | 2,000,000.00 | 41,000,000.00 |
| Other Adjustments To Reconcile Profit Loss | -263,000,000.00 | 0.00 |
| Cash Flows From Used In Operations | 1,153,000,000.00 | 1,679,000,000.00 |
| Interest Received Classified As Operating Activities | 17,000,000.00 | 17,000,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | 72,000,000.00 | 126,000,000.00 |
| Other Inflows Outflows Of Cash Classified As Operating Activities | 119,000,000.00 | 170,000,000.00 |
| Cash Flows From Used In Operating Activities | 1,081,000,000.00 | 1,553,000,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | 1,986,000,000.00 | 0.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | 1,000,000.00 | 1,000,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 256,000,000.00 | 282,000,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | 93,000,000.00 | 211,000,000.00 |
| Purchase Of Other Longterm Assets Classified As Investing Activities | 7,000,000.00 | 19,000,000.00 |
| Other Inflows Outflows Of Cash Classified As Investing Activities | 75,000,000.00 | 15,000,000.00 |
| Cash Flows From Used In Investing Activities | -2,228,000,000.00 | -487,000,000.00 |
| Payments To Acquire Or Redeem Entitys Shares | 106,000,000.00 | 60,000,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | 1,895,000,000.00 | 0.00 |
| Repayments Of Borrowings Classified As Financing Activities | 166,000,000.00 | 512,000,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | 41,000,000.00 | 40,000,000.00 |
| Dividends Paid Classified As Financing Activities | 235,000,000.00 | 240,000,000.00 |
| Interest Paid Classified As Financing Activities | 70,000,000.00 | 63,000,000.00 |
| Cash Flows From Used In Financing Activities | 1,177,000,000.00 | -1,119,000,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 30,000,000.00 | -53,000,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | -15,000,000.00 | -7,000,000.00 |
| Cash and cash equivalents | 1,336,000,000.00 | 1,263,000,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 02.03.22 | van Zyl Charl | Executive member | Sell | EUR 1,384,570.46 |
| 02.03.22 | van Zyl Charl | Executive member | Buy | EUR 921,821.22 |
| 26.08.21 | Caeymaex Emmanuel | Executive member | Sell | EUR 393,320.00 |
| 26.08.21 | Caeymaex Emmanuel | Executive member | Buy | EUR 269,400.00 |
| 25.08.21 | Caeymaex Emmanuel | Executive member | Sell | EUR 469,802.45 |
| 25.08.21 | Caeymaex Emmanuel | Executive member | Buy | EUR 275,779.40 |
| 01.08.21 | Lund- Jürgensen Kirsten | Executive member | Buy | EUR 328,622.94 |
| 21.05.21 | Loew-Friedrich Iris | Executive member | Sell | EUR 468,960.00 |
| 27.11.20 | Caeymaex Emmanuel | Executive member | Sell | EUR 90,400.00 |
| 27.11.20 | Caeymaex Emmanuel | Executive member | Sell | EUR 90,020.00 |
BE0003739530
LEI2138008J191VLSGY5A09
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryBEL20
Main Stock ExchangeKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.